Phase I Clinical Study of Oral Olaparib in Pediatric Patients with Refractory Solid Tumors
Latest Information Update: 25 May 2022
At a glance
- Drugs Olaparib (Primary)
- Indications Neuroblastoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions
- 20 May 2022 Results published in the Cancer
- 28 Jun 2021 Status changed from active, no longer recruiting to completed.
- 04 Sep 2020 Status changed from recruiting to active, no longer recruiting.